These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 7789889)

  • 1. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
    Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
    Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between CA125 half life during neoadjuvant chemotherapy and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma].
    Xi XW; Wan XP; Li SD; Sun TW; Zhu YP
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):91-4. PubMed ID: 16640855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
    Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
    Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
    Riedinger JM; Eche N; Basuyau JP; Dalifard I; Hacene K; Pichon MF
    Gynecol Oncol; 2008 May; 109(2):194-8. PubMed ID: 18329083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study].
    Riedinger JM
    Bull Cancer; 2007 Mar; 94(3):287-95. PubMed ID: 17371771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
    Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
    Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
    Lan CY; Huang H; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M; Federico M; Liu PY; Hannigan E; Alberts D
    Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].
    Riedinger JM; Barillot I; Coudert B; Fargeot P; Berriolo-Riedinger A; Guerrin J
    Bull Cancer; 1996 Aug; 83(8):654-63. PubMed ID: 8869046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
    Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
    J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer.
    Kolwijck E; Span PN; Thomas CM; Bulten J; Sweep FC; Massuger LF
    Oncol Rep; 2010 Feb; 23(2):579-84. PubMed ID: 20043124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
    Begum FD; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Christensen L; Høgdall C
    Acta Obstet Gynecol Scand; 2010; 89(2):190-8. PubMed ID: 20121334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer.
    Kang S; Seo SS; Park SY
    J Surg Oncol; 2009 Sep; 100(3):244-7. PubMed ID: 19267361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study.
    Gadducci A; Sartori E; Maggino T; Zola P; Landoni F; Fanucchi A; Palai N; Alessi C; Ferrero AM; Cosio S; Cristofani R
    Gynecol Oncol; 1998 Feb; 68(2):150-5. PubMed ID: 9514797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
    Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.